Showing 1 - 4 of 4 Skin Cancers
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab. ... Read more >

CDX-1140 : A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined. ... Read more >

Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator: Lacey Burey

Phone: 713.441.1159

The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >

Live Chat Available